Although amylin was discovered decades ago, its importance in everyday clinical practice has long been underestimated. New pharmacological developments are increasingly bringing amylin into the focus of diabetes and obesity therapy, and amylin analogs, some of which have already passed phase 3 clinical trials, are now among the most promising approaches in overweight and obesity pharmacotherapy.
Autoren
- Dr. Stephanie Niklaus
- Prof. Dr. med. vet. Thomas A. Lutz
Publikation
- InFo DIABETOLOGIE & ENDOKRINOLOGIE
Related Topics
You May Also Like
- Diabetes mellitus
Treatment of comorbidities in older people
- Alternative to insulin and GLP1
From the β-cell to the center: the versatile role of amylin
- Pulmonary sarcoidosis
Prednisone vs. MTX: a draw after 24 weeks
- Friedreich's ataxia
Loss of orientation in the cerebellum
- Diabetes mellitus
Treatment of comorbidities in older people
- Artificial intelligence
Dr. ChatGPT: Large language models in everyday clinical practice
- Subtyping as the key to precision medicine
Molecular diversity of the PDAC
- Multiple sclerosis